Omeros Corporation

ABICOMP

Medical information services, namely, providing information concerning pharmaceutical and biopharmaceutical products, and therapeutic methods in the fields of endothelial diseases and disorders, renal diseases, transplant complications, ischemia reperfusion injury, hematological, autoimmune, immunological and inflammatory related diseases and disorders;Research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the fields of pharmaceuticals and biopharmaceuticals;

ACTIVATION BLOCKER OF INNATE COMPLEMENT

Research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the fields of pharmaceuticals and biopharmaceuticals; medical information services, namely, providing information concerning pharmaceutical and biopharmaceutical products, and therapeutic methods;

ARTEMLEA

Pharmaceutical preparations for the treatment of endothelial diseases and disorders, renal diseases, transplant complications, ischemia-reperfusion injury and hematological, autoimmune, neurological, immunological and inflammation-related disease and disorders; biologics for the treatment of endothelial diseases and disorders, renal diseases, transplant complications, ischemia-reperfusion injury and hematological, autoimmune, neurological, immunological and inflammation-related disease and disorders;

ARTHROSOL

Pharmaceutical preparations for the treatment of orthopedic joint trauma;

ARTHROSOL

Pharmaceutical preparations for the treatment of orthopedic trauma;

ARTHROSOL

Pharmaceutical preparations for the treatment of orthopedic trauma;

ARTHROSOL

Pharmaceutical preparations for the treatment of orthopedic trauma;

CAT-T

Providing medical information;Medical and scientific research information in the field of pharmaceuticals, biopharmaceuticals, and clinical trials; Research and development in the pharmaceutical and biotechnology fields;

EDELIQ

Pharmaceuticals, namely, pharmaceutical preparations for ocular or intraocular surgery;The wording EDELIQ has no meaning in a foreign language.;

EDYLIQ

Pharmaceuticals, namely, pharmaceutical preparations for ocular or intraocular surgery;The wording EDYLIQ has no meaning in a foreign language.;

EFOCEA

Pharmaceuticals, namely, pharmaceutical preparations for ocular or intraocular surgery;The wording EFOCEA has no meaning in a foreign language.;

EFOCEA

Pharmaceuticals, namely, pharmaceutical preparations for ocular or intraocular surgery;The wording EFOCEA has no meaning in a foreign language.;

EFOCEA

Pharmaceutical preparations for complement-mediated diseases, addiction and oncology, none of the foregoing in connection with pharmaceutical preparations for the treatment of dermatological diseases and conditions;The wording EFOCEA has no meaning in a foreign language.;

ICAB

Medical information services, namely, providing information concerning pharmaceutical and biopharmaceutical products, and therapeutic methods in the fields of endothelial diseases and disorders, renal diseases, transplant complications, ischemia reperfusion injury, hematological, autoimmune, immunological and inflammatory related diseases and disorders;Research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the fields of pharmaceuticals and biopharmaceuticals;

IMPROVE THE OUTLOOK FROM THE INSIDE

Pharmaceutical preparations for the treatment of endothelial diseases and disorders, renal diseases, transplant complications, ischemia-reperfusion injury and hematological, autoimmune, neurological, immunological and inflammation-related disease and disorders; biologics for the treatment of endothelial diseases and disorders, renal diseases, transplant complications, ischemia-reperfusion injury and hematological, autoimmune, neurological, immunological and inflammation-related disease and disorders;Printed publications in the nature of brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support;Medical information services, namely, providing information concerning pharmaceutical and biopharmaceutical products, and therapeutic methods in the fields of endothelial diseases and disorders, renal diseases, transplant complications, ischemia reperfusion injury, hematological, autoimmune, immunological and inflammatory related diseases and disorders;Providing medical and scientific research information in the fields of pharmaceuticals and biopharmaceuticals;

INNATE COMPLEMENT ACTIVATION BLOCKER

Research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the fields of pharmaceuticals and biopharmaceuticals; medical information services, namely, providing information concerning pharmaceutical and biopharmaceutical products, and therapeutic methods;

LET SCIENCE LEAD THE WAY

Medical information services, namely, providing information concerning pharmaceutical and biopharmaceutical products, and therapeutic methods in the fields of endothelial diseases and disorders, renal diseases, transplant complications, ischemia reperfusion injury, hematological, autoimmune, immunological, and inflammatory related diseases and disorders, and oncology, addiction, compulsive, and movement related diseases and disorders;Providing medical and scientific research information in the fields of pharmaceuticals and biopharmaceuticals;

NEXT-GENERATION THERAPEUTICS TRANSFORMING PATIENT CARE TODAY

The drawing is amended to appear as follows: NEXT-GENERATION THERAPEUTICS TRANSFORMING PATIENT CARE TODAY. In the statement, a disclaimer of any right to THERAPEUTICS apart from the mark is inserted.;THERAPEUTICS;Medical and scientific research in the field of inflammation, coagulopathies and disorders of the central nervous system;

OMASPLEA

Pharmaceutical preparations for the treatment of endothelial diseases and disorders, renal diseases, transplant complications, ischemia-reperfusion injury and hematological, autoimmune, neurological, immunological and inflammation-related disease and disorders; biologics for the treatment of endothelial diseases and disorders, renal diseases, transplant complications, ischemia-reperfusion injury and hematological, autoimmune, neurological, immunological and inflammation-related disease and disorders;

OMEROS

pharmaceuticals, namely-- surgical and burn management compositions containing pharmacologic agents for the inhibition of pain, inflammation, cartilage loss, smooth muscle spasm and/or tumor cell adhesion associated with surgical procedures and other trauma; chondroprotective compositions containing pharmacologic agents for the treatment or inhibition of cartilage loss, pain and/or inflammation; intravascular compositions containing pharmacologic agents for the inhibition of vasospasm and/or restenosis; and drug delivery systems, namely combinations of pharmacologic agents or genes and their carriers for the treatment and inhibition of pain, inflammation, cartilage loss, smooth muscle spasm, tumor cell adhesion, vasospasm and/or restenosis;Omeros may be translated as the Greek version of Homer.;

OMEROS

Pharmaceuticals, namely -- surgical compositions containing pharmacologic agents for the inhibition of pain, inflammation, cartilage loss, smooth muscle spasm and/or cell adhesion, for promoting mydriasis and/or for controlling intraocular pressure associated with surgical, diagnostic, therapeutic or medical procedures and other trauma; chondroprotective compositions containing pharmacologic agents for the treatment or inhibition of cartilage loss, pain and/or inflammation; pharmacologic agents and antibodies for the inhibition of the complement immune system; pharmacological agents for the treatment of schizophrenia and other psychiatric disorders; pharmacological agents for the treatment of Parkinson's disease and other neuromuscular and neurodegenerative disorders; pharmacological agents for the treatment of obesity and other metabolic disorders; pharmacological agents for the treatment or inhibition of pain; pharmacological agents for the treatment of sleep and attention deficit disorders; and drug delivery systems, namely pharmacologic agents or antibodies carried in a hydrogel or micellular delivery vehicle;The English translation of the word OMEROS in the mark is HOMER.;

OMEROS

The mark consists of stylized OMEROS plus design including superimposed stylized alpha and omega symbols.;Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for the treatment of pain and inflammation during orthopedic surgery; Pharmaceutical preparations for the treatment of pain, inflammation and smooth muscle spasm during urological procedures; Pharmaceutical preparations for the treatment of arthritis; and Pharmaceutical preparations for the treatment of addiction and alcoholism;Color is not claimed as a feature of the mark.;The foreign wording in the mark translates into English as Homer.;